Posted by su1801 > 2021-06-04 12:18 | Report Abuse
My opinion kanger will have bright future..... if sucsess it will be next bintai and solutn
Posted by MZM2511 > 2021-06-06 04:39 | Report Abuse
UPDATED NEWS...
KJ sahkan ada pihak tempatan cuba daftar vaksin Sinopharm
Menteri Penyelaras Program Imunisasi COVID-19 Kebangsaan sahkan terdapat beberapa pihak tempatan yang sedang cuba mendaftarkan vaksin Sinopharm dihasilkan syarikat farmaseutikal dari China. Vaksin sinopharm tidak termasuk di dalam Program Imunisasi COVID-19 Kebangsaan (PICK). Kata Khairy Jamaluddin, perkara berkenaan adalah dibenarkan dan pihaknya mengalu-alukan perkara tersebut. (May 21, 2021)
Sumber: https://www.astroawani.com/video-malaysia/covid-19-kj-sahkan-ada-pihak-tempatan-cuba-daftar-vaksin-sinopharm-1905361
Posted by MZM2511 > 2021-06-14 08:16 | Report Abuse
Setakat ini, katanya, Malaysia hanya meluluskan penggunaan vaksin Pfizer, Sinovac dan AstraZeneca sedangkan Pertubuhan Kesihatan Dunia (WHO) telah menyenaraikan Johnson & Johnson, Moderna dan Sinopharm untuk kegunaan kecemasan di seluruh dunia.- Hishammuddin Hussein
Sumber: https://www.malaysiakini.com/news/578764
Posted by MZM2511 > 2021-06-22 08:30 | Report Abuse
An update on the prospect of Kanger to be involved as the distributor of Sinopharm Covid-19 vaccine in Malaysia:
Report 1: 9 March 2021.
Kanger International Bhd will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes.
In a bourse filing today, the group said the 10,000 doses of the vaccine will be for trial purposes and that it will be getting the necessary approvals from the relevant authorities.
“The first batch of vaccines is expected to arrive in May 2021,” Kanger stated.
Sinopharm has Covid-19 vaccine candidates that are undergoing stage 3 clinical trials
Source: https://www.theedgemarkets.com/article/kanger-receive-10000-doses-sinopharm-covid19-vaccine%C2%A0-may-trial-purposes
Report 2: 21 May2021.
The government is open to any party that has the capability and clinical data of the Sinopharm Covid-19 vaccine to register it with the National Pharmaceutical Regulatory Agency (NPRA), says Khairy Jamaluddin (pic).
The National Covid-19 Immunisation Programme coordinating minister said that this DID NOT HAVE TO GO THROUGH PHARMANIAGA, the local registration product holder for the Sinovac vaccine.
He said there were several parties interested in bringing the Sinopharm vaccine from China.
“It can go through anybody else who wants to try and bring in the vaccine. It can be registered with the NPRA,” he said in a video late Thursday (May 20) to address several allegations made by Opposition leader Datuk Seri Anwar Ibrahim about the immunisation programme.
Source: https://mywinet.com/covid-19-those-who-want-to-bring-in-sinopharm-vaccine-can-register-it-with-npra-says-khairy/
Report 3: 27 May2021.
“the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.” Source: https://www.freemalaysiatoday.com/category/nation/2021/05/27/sabah-signs-mou-with-private-firm-to-obtain-sinopharm-vaccine/
MY FINDINGS:
1. Kanger planned to bring Sinopharm Covid-19 vaccine for trial purposes.
2. Until 21 May 2021, the Sinopharm Covid-19 vaccine was not registered with NPRA yet.
3. There will be a big probability that the report by Kanger official is true. The company has started to register the said vaccine with NPRA.
Posted by MZM2511 > 2021-06-22 09:48 | Report Abuse
On the Sputnik Covid-19 vaccine produced by Russia, Khairy said that Duopharma Biotech Bhd’s wholly-owned subsidiary, Duopharma (M) Sdn Bhd (DMSB), which holds the distribution rights to the product, has three months to register the vaccine with the National Pharmaceutical Regulatory Agency (NPRA), after inking an agreement with the government earlier this month.
He said that the NPRA still requires further information on the vaccine.
“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO). Sputnik has not received the EUL from WHO yet,” he said, referring to the Emergency Use Listing.
Source: https://www.malaymail.com/news/malaysia/2021/06/21/khairy-cansino-vaccine-to-arrive-in-malaysia-next-month-no-updates-yet-on-j/1983852
Posted by MZM2511 > 2021-06-22 09:48 | Report Abuse
“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO).
--------------------
I want to stress on this.
If the Sinopharm was truly just registered with NPRA, the process of approval should be more shorter in time compared with the vaccine candidate which not been approved by WHO yet.
Note: Sinopharm vaccine has been approved by WHO,
Posted by MZM2511 > 2021-06-24 19:00 | Report Abuse
Khairy also mentioned that Covid-19 vaccines will enter the private market by August. He said that private vaccination will help the government ramp up the national Covid-19 vaccination programme, as those who are able to pay for the vaccines will be able to do so.
“I also anticipate by about August, we will have a private vaccine market. So right now, it’s difficult for private because vaccines are in short supply. But by August, I think that there will be some companies who will be approved to bring in some private vaccines from China. I know Sinopharm and all that are going to be registered here,” Khairy added.
“That’s also part of the plan. I’ve been talking to the Ministry of Health to ensure that the private market by August can take off to help us.”
Source: https://codeblue.galencentre.org/2021/06/24/khairy-projects-40-population-fully-vaccinated-by-end-august/
Posted by MZM2511 > 2021-07-15 20:58 | Report Abuse
Dr Noor Hisham: NPRA set to announce Sinopharm’s inclusion in Covid-19 immunisation plan
“Tomorrow the NPRA will meet and we will consider the Sinopharm vaccine, which was approved by the World Health Organisation.
“Their company just sent their dossiers to us, and in less than a month we have evaluated and will give our decision on the conditional approval tomorrow,” he said.
Source: https://malaysia.news.yahoo.com/dr-noor-hisham-npra-set-111805262.html
Posted by MZM2511 > 2021-07-19 13:41 | Report Abuse
The Board of Directors of Kanger (“Company”) wishes to announce that Kanger Medical International Sdn. Bhd., a wholly-owned subsidiary of the Company had, on 19 July 2021 entered into Head of Agreement with Sparmak Medical Equipment Trading LLC for purchase of inactivated SARS-COV-2 Vaccines (Vero Cell) vaccine developed by Beijing Institute of Biological Products Co. Ltd., an affiliate of SINOPHARM CNBG.
Please refer to the full announcement as attached.
This announcement is dated 19 July 2021.
Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3176295
4.1 Quantity and specification of the Products
Quantity: Five Million (5,000,000) doses with an option to buy an additional Five Million (5,000,000) doses.
Specification: SARS COV-2 vaccine (Vero cell) inactivated, 6.5 U/0.5ml in prefilled syringe or vial (as per availability) and pack size either 2 doses per vial per box or Single dose per vial per box (as per availability). The Product is manufactured by Gulf Pharmaceutical Industries Julphar in the United Arab Emirates (HAYAT-VAX), i.e. G42 Medications Trading LLC (“Manufacturer”).
Posted by MZM2511 > 2021-07-19 17:39 | Report Abuse
Earlier this year, Sinopharm entered into a joint venture with UAE-based G42 to produce the Sinopharm Covid-19 vaccines in the country under the Hayat-Vax brand.
The made-in-UAE vaccine was the first Covid-19 vaccine to be produced in the Arab world.
"The Hayat-Vax vaccine is essentially the same Sinopharm Covid-19 vaccine, manufactured in the UAE. Hence, we are confident that it will be well-received and accepted by the Malaysian people as an effective vaccine towards the global fight against the Covid-19 pandemic," said Kuah.
Kanger has also been authorised by G42 to be the product registration holder and distributor of the Hayat-Vax vaccine in Malaysia.
On behalf of G42 Medications, Kanger said it had submitted applications to obtain the required approvals from the National Pharmaceutical Regulatory Agency for the Hayat-Vax vaccine to be used in Malaysia.
No result.
3
save malaysia!
4
BFM Podcast
5
BFM Podcast
8
BFM Podcast
#
Stock
Score
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock
Time
Signal
Duration
Stock
Time
Signal
Duration
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
MZM2511
4,549 posts
Posted by MZM2511 > 2021-06-04 12:03 | Report Abuse
1. Perjanjian sebagai SOLE DISTRIBUTOR yang dilantik untuk 3 tahun oleh Sinopharm dah ada - SETTLE
Sumber: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3092107
2. MOU untuk wakil distributor bagi pihak Kanger dah ada iaitu Zuellig Pharma - SETTLE
Sumber:
1. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3154098
2. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3137884
Nota: Kanger will collaborate with ZP to facilitate the import, warehousing, and
distribution of Covid-19 vaccines in Malaysia. Kanger will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes. The first batch of vaccines is expected to arrive in Malaysia on May 2021).
3. MOU untuk saluran jualan vaksin ke kilinik swasta di Malaysia dah ada iaitu KSport - SETTLE
Sumber:
1. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3154097
2. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3137884
SEKARANG TUNGGU UNTUK PROSES APPROVAL OLEH KERAJAAN DAN NPRA SAHAJA.